1841722439
Method Made: The Tech Transfer Edge in Cell & Gene Therapy

Advertise on podcast: Method Made: The Tech Transfer Edge in Cell & Gene Therapy

This podcast has
50 episodes
Language
English
Publisher
Nico
Explicit
No
Date created
2025/09/23
Latest episode
2026/11/03
Average duration
37 min.
Release period
8 days

Description

In the competitive cell and gene therapy landscape, speed and efficiency are paramount. The biggest roadblock? The operational friction in tech transfer. This podcast is for executives focused on building a durable competitive advantage. We explore how to transform tech transfer from your biggest risk into your greatest asset. By solving the deep operational challenges and aligning perfectly with your CDMO partner, you can shorten timelines, protect capital, and get your therapy to patients faster. Move beyond day-to-day problems and learn to build a tech transfer strategy that wins.

Unlock Method Made: The Tech Transfer Edge in Cell & Gene Therapy podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Method Made: The Tech Transfer Edge in Cell & Gene Therapy podcast


Solving the CGT Workforce Deficit & 50% CAR-T Attrition Gap | Dr. Shernan Holtan
2026/11/03
Despite rapid innovation in cell and gene therapy, clinical operational bottlenecks from severe workforce deficits to high geographic attrition continue to limit patient access. In this episode of Out of the Lab, host Nico Crudele sits down with Dr. Shernan Holtan, Chief of Blood and Marrow Transplantation and Professor of Medicine at Roswell Park Comprehensive Cancer Center. Dr. Holtan breaks down the workforce shortage facing cell therapy, the physiological reality of clinical decision fatigue, and why nearly 50% of referred CAR-T patients never receive treatment. She outlines practical operational solutions, including personalized clinical scheduling, predictive toxicity biomarkers (ferritin, CRP, physical mobility metrics), and Roswell Park's innovative Hub-and-Spoke shared care model designed to bring advanced therapies closer to community settings. Timestamps & Key Topics: 00:00:00 – Introduction & The Clinical Workforce Shortfall 00:05:00 – Why Medical Trainees Bypass Cell Therapy & BMT 00:08:48 – The 1,300 Physician Deficit & Post-Pandemic Burnout 00:15:43 – 400 Decisions a Day: Addressing Clinical Decision Fatigue 00:20:00 – The 50% Attrition Rate: Travel and Logistical Barriers in Rural Access 00:23:05 – Decentralizing Delivery: The "Hub-and-Spoke" Shared Care Model 00:28:03 – Standardizing Contingency Planning & The Role of APPs 00:31:31 – Operationalizing Predictability: Ferritin, CRP, and Physical Mobility Scoring
In Vivo Lenti, COGS Reduction, and the End Game Mindset with Ethan (Minaris)
2026/10/27
In this episode of Out of the Lab, host Nicholas Crudele sits down with Eytan Abraham, President, Minaris Viral Vectors. Together, they explore the emerging wave of in vivo lentiviral vectors (LVV) and the critical operational shifts required to move from personalized ex vivo CAR-T to off-the-shelf therapies. Ethan breaks down why traditional viral vector manufacturing faces severe yield losses during downstream purification, how early choices in cell lines and plasmids dictate final COGS, and why early-stage biotechs must begin with the "end game" in mind to ensure commercial reimbursement. Key Topics Covered: The In Vivo LVV Shift: Moving gene editing from outside the body (ex vivo) to inside the patient (in vivo). Tackling Upstream & Downstream Yield Losses: How producer cell lines and purification efficiencies lower cost per patient. The "End Game" Mindset: Why pricing, scale, and insurer reimbursement must be designed prior to Phase 1. Selecting the Right CDMO Partner: Questions founders must ask about tech transfer track records and platform leverage. Bridging Academic Silos: Educating PIs on translational manufacturing before locking in suboptimal processes.
Rare Disease Commercialization: Lean Market Entry & Virtual Subsidiaries | Chad (ChangDeok) Ji
2026/10/20
In this episode of Out of the Lab, host Nicholas Crudele sits down with 20-year rare disease veteran Chad to dissect the operational hurdles of commercializing specialized therapies globally. Traditional big pharma launch models rely on heavy local infrastructure and massive fixed overhead: a formula that creates unsustainable burn rates for biotechs targeting ultra-rare patient populations. Chad outlines how emerging biotechs can maintain strategic control, navigate complex APAC market access dynamics, and launch efficiently using lean operational frameworks. Key Topics Discussed: The Infrastructure Gap: Why traditional local-affiliate expansion models burn cash too quickly in ultra-rare diseases. The 4S Launch Model: Building commercial setups that are Smaller, Specialized, Speed-driven, and Sustainable. The Virtual Subsidiary Approach: How to rent local execution infrastructure without relinquishing strategic control to third-party distributors. Navigating APAC Market Access: Utilizing pragmatic pricing strategies and confidential risk-sharing deals in South Korea to protect global reference pricing. Network Orchestration: Governing external partner networks with a unified launch master plan to avoid fragmented execution. Timestamps: 00:00:00 – Introduction & Method Made Operational Intelligence 00:01:04 – Chad's Background in Rare Disease Commercialization 00:02:24 – The Heavy Infrastructure Gap in Traditional Pharma Launches 00:04:15 – Breaking Down the 4S Launch Framework 00:05:48 – Virtual Subsidiaries vs. Distributor Trade-Offs 00:09:05 – Execution Friction & Market Access in APAC / South Korea 00:11:08 – When to Align Global Reimbursement Strategies 00:12:43 – Orchestrating Partner Networks & Governing Execution 00:15:35 – Sustainable Operations & Long-Term Patient Access
Point-of-Care Bottlenecks, Portal Fatigue & SOP Ambiguity with Dr. Patrick Hanley
2026/10/13
While commercial cell and gene therapies are transforming medicine, academic medical centers face a massive, operational burden when delivering them. From juggling separate vendor software portals to guiding lost couriers carrying $3M therapies through hospital corridors, point-of-care delivery is fraught with administrative and physical friction. In this episode of Out of the Lab, host Nico Crudele sits down with Dr. Patrick Hanley, Director of Cellular Therapy at Children's National Hospital. Together, they break down the real-world disconnects between commercial biopharma developers, hospital stem cell labs, and final patient delivery. Key Topics Discussed: Portal Fatigue: Why custom vendor portals, IT approvals, and unique qualification forms create immense administrative overhead for hospital staff. The Hospital Shipping Strain: How commercial manufacturing delays and re-collections caused a hospital cell lab's shipment volume to explode from near zero to 90+ shipments annually. Tacit Knowledge in Tech Transfer: How terms like "gently resuspend" or "ice-cold PBS" lead to cracked flasks, variable yields, and batch failures. Decentralized Manufacturing & Regulatory Pathways: Exploring rapid BLA mechanisms and point-of-care models for rare pediatric diseases. Training Beyond Hardware: Why the industry over-indexes on equipment training while ignoring essential quality soft skills like deviation writing and root-cause analysis. Brought to you by Method Made. Accelerate your tech transfer by up to six months using video SOPs to capture technical nuance. Download the free Tech Transfer Failure Modes and Effects Analysis at methodmade.ca.
Restoring Patient Agency: Breaking the 80% Access Barrier in Cell Therapy | Michelle Hill
2026/10/06
In this episode of Out of the Lab, host Nico Crudele sits down with Michelle Hill, a 30-year biotech veteran, Kite Gilead alum and founder of Avenue to Care, to examine why revolutionary cell therapies like CAR T are failing to reach over 80% of eligible patients. Michelle breaks down the severe non-clinical, operational, and socioeconomic barriers keeping advanced treatments locked behind elite academic medical centers. From community physician referral gaps and geographic attrition to building data-neutral care orchestration platforms, this conversation explores how the industry can bridge the gap between treatment availability and true patient access. Key Takeaways: Why CAR T adoption has plateaued at 20% and how current access disproportionately favors patients with health literacy and financial means. How general oncologists' lack of familiarity with cell therapy risks and successes creates early patient drop-outs. The role of non-clinical care orchestration in restoring patient agency without crossing pharma compliance boundaries. Navigating post-treatment survivorship, long-term follow-up registry demands (CIBMTR), and the impact of REMS updates on patient travel requirements. Timestamps & Key Topics: 00:00:00 – Introduction & Method Made Sponsor 00:01:16 – The 80% Access Deficit & Infrastructure Gaps 00:03:32 – The 10-Mile Rule & Geographic Attrition 00:06:26 – Early Diagnoses & The Loss of Patient Agency 00:11:32 – Rare Disease, Autoimmune, and the CAR T Horizon 00:14:07 – General Oncologist Referral Hesitancy & Perceived Failures 00:17:03 – Socioeconomic Privilege in Clinical Access 00:22:17 – Introducing Avenue to Care: Public Benefit Care Orchestration 00:26:34 – Post-Treatment Care, Survivorship, & Long-Term Data Tracking 00:31:07 – Global Access Challenges & Health Literacy 00:35:12 – Rebuilding Healthcare Around the Patient
The 2 AM Audit Reality: Ex-FDA Regulators on CDMO Oversight, Night Shift Sins, and Data Integrity
2026/09/29
Why do processes that look clean on paper collapse during an FDA inspection? In this episode of Out of the Lab, host Nico Crudele sits down with ex-FDA auditors DeVaughn Edwards (GMP specialist) and Elvia Cervantes (GCP specialist) to break down the most common and preventable compliance disasters in cell and gene therapy. From night-shift compliance breakdowns and paper-only CDMO audits to data manipulation and informal quality decisions, DeVaughn and Elvia share unvarnished insights from their time inside the agency and in the field. Key Takeaways: You Can't Outsource Liability: Why delegating manufacturing to a CDMO or clinical monitoring to a CRO does not clear a sponsor's regulatory responsibility. The "Boots on the Ground" Mandate: Why paper questionnaires fail vendor qualification and how unmonitored night shifts breed compliance failures. Building Code vs. Blueprint: The cost of bringing Quality teams in midstream rather than from project inception. Data Integrity Realities: What actual record destruction and email-based decision-making signal to FDA investigators. Modern Audit Readiness: How remote regulatory assessments (RRAs), 1-day audits, and AI tools like ELSA are changing FDA oversight. Timestamps / Show Notes: 00:01:16 – The cost of involving Quality teams too late in development. 00:05:29 – Qualifying CDMOs: Why "boots on the ground" beat paper questionnaires. 00:09:08 – The 2 AM reality check: Night shift compliance breakdowns. 00:14:00 – Modern audit readiness, 1-day inspections, and FDA’s ELSA system. 00:24:43 – Data integrity red flags: Document destruction and pressure-driven cover-ups. 00:41:33 – Operational silos: When administrative assistants make escalation decisions. 00:47:32 – What an effective CAPA actually looks like. 01:05:15 – Inspecting emails and server migrations as regulatory liabilities.
The $1M CDMO Selection Trap & Rethinking CMC Roadmaps with Shri Joshi
2026/09/22
Why does selecting the cheapest CDMO quote often lead to millions of dollars in unexpected costs down the road? In this episode of Out of the Lab, host Nico sits down with industry veteran Shri Joshi, who has navigated cell and gene therapy operations across consulting, CDMO, and sponsor sides to break down the core ingredients of a successful drug development lifecycle. We explore why CDMO selection must be treated as a development and risk-management decision rather than a simple procurement task. Shri breaks down why early investments in analytical methods create crucial operational flexibility, why the adage "the process is the product" can actually harm development, and how early-stage founders can build a true "comparability mindset" to de-risk clinical progression. Key Topics Covered: 00:01:34 – The 3 core ingredients of cell & gene therapy development 00:04:20 – Why CDMO selection is a risk management decision, not procurement 00:07:28 – Case Study: Transparency vs. unrealistic timeline promises 00:18:38 – The real cost of cheap contracts: How a $1M discount cost $5M later 00:21:41 – CMC 101: Chemistry, Manufacturing, & Controls explained 00:24:37 – Why "the process is the product" dogma creates operational bottlenecks 00:27:53 – Developing analytical methods early to enable comparability 00:32:04 – Utilizing Quality Target Product Profiles (QTPP) & Process Flow Diagrams This episode is brought to you by Method Made. Accelerate your tech transfer by up to six months using video SOPs to capture technical nuance. Download the free Tech Transfer Failure Modes and Effects Analysis at methodmade.ca by clicking Download FMEA.
Bunny Suits, Ice Buckets, and Slashing COGS: Bridging R&D and GMP Realities with Jerry (CellBri)
2026/09/15
Why do brilliant R&D processes stall or fail when transferred into a GMP cleanroom? In this episode of Out of the Lab, host Nicholas Crudele sits down with Jerry from CellBri to unpack the unspoken assumptions, technical miscommunications, and equipment hurdles that delay cell therapy manufacturing. From the reality of using ice buckets instead of precise 4°C incubation to reducing batch COGS from $150,000 down to under $20,000 using flexible automation, Jerry breaks down how effective communication through documentation and smart software UX de-risk cell therapy scale-up. Key Topics Covered: The R&D vs. Cleanroom Disconnect: Why gowning, double-gloving, and workflow timing ruin unexamined bench protocols during tech transfer. The "Oral Tradition" Trap: How minor miscommunications (0°C vs. 4°C) can cause month-long troubleshooting investigations. Slashing COGS with Flexible Automation: How modern automated systems dramatically cut labor costs and production days. UX in the Cleanroom: Replacing ambiguous error codes with on-screen video guidance to prevent catastrophic batch losses.
Beyond Manufacturing: Why Portal Fatigue and Physician Adoption Are Blocking Cell Therapy Access
2026/09/08
Is manufacturing complexity really the main bottleneck holding back cell and gene therapies, or are we ignoring the operational friction occurring right at the physician's desk? In this episode of Out of the Lab, host Nicholas Crudele sits down with Carl Schoellhammer, Partner at DeciBio, to discuss why the cell therapy industry must shift its focus from cleanroom COGS to physician awareness, simplified prescribing workflows, and clinical adoption. Carl shares his perspective on the barriers stalling patient access, comparing centralized US logistics with Europe’s decentralized hospital exemption framework and explaining why the key to scaling cell therapies lies in streamlining the entire prescribing journey. Key Takeaways: The Manufacturing Fallacy: Why COGS and production complexity are no longer the primary bottlenecks limiting cell therapy scale. Portal Fatigue: How fragmented drug scheduling systems force doctors to hunt for passwords on Post-it notes just to write a script. The European Exemption Model: How centers like Hospital Clínic de Barcelona are leveraging hospital exemption acts to dose over 500 patients in-house. Solving Logistics: Easing the administrative and travel burdens on non-metropolitan patients. Predictive Operations: How automated analytics and process monitoring can drastically lower batch failure rates.
The End of the Supply Chain Is the Patient: Shortages, Governance, and Risk with Dr. Angeliki Kotsianti
2026/09/01
What happens when a biopharma supply chain breaks upstream from the clinic? It doesn't just delay manufacturing, it forces doctors at the bedside to choose which patients receive curative therapy and which ones have to wait. In this episode of Out of the Lab, host Nicholas Crudele sits down with Dr. Angeliki Kotsianti, founder and scientific advisor of Oncolyze and former Senior Global Medical Benefit Risk Lead at Pfizer. Drawing on her unique perspective as both a treating physician and a senior biopharma executive, Angeliki breaks down why drug shortages must be re-framed as clinical events, how evolving regulatory guidance (like Computer Software Assurance) demands human medical judgment, and why operational governance must be engineered into drug development from day one. Key Takeaways: The Bedside Realities of Shortages: Lessons from the 2009 oncology supply chain crisis and why single-source dependencies leave zero buffer for clinical delivery. Shortage as a Clinical Event: How manufacturing line downtime, API consolidation, and quality deviations directly impact medical choices and patient survival. Human Accountability vs. Automation: Why software tools cannot take management decisions or replace clinical judgment when evaluating patient exposure. Designing the Line from the Outset: Why operationalizing advanced therapies requires one owner across the entire pathway from bench to patient.
Global Competition, Tech Transfer Traps, and Cost Reduction Realities with Alfred Sloan
2026/08/25
In this episode of Out of the Lab, host Nico sits down with 20-year cell and gene therapy expert Alfred Sloan to dissect the operational and capital constraints facing advanced therapy development today. From the pressure to rapidly accelerate clinical timelines to the rising threat of global competition outcasting domestic manufacturing costs, Alfred breaks down why the industry must shift from isolated IP retention to scalable, repeatable manufacturing frameworks. Key Discussion Points: The Scalability Gap: Why existing technologies fail to scale seamlessly from research to commercial production. Global Competition & Medical Tourism: How overseas government subsidies and collaborative models threaten to outpace US manufacturing within five years. Tech Transfer Traps: Why handing over a paper SOP to a CDMO leads to $100,000 run failures and how continuous technical support bridges the gap. Operational Cost Reduction: Navigating master service agreements, expediting fees, modular "widget" approaches, and standardizing assembly-line manufacturing. Timestamps: 00:01:25 – Capital Constraints and Clinical Acceleration 00:03:27 – The Scalability Bottleneck Across Development Stages 00:06:28 – Breaking Down Knowledge Sharing and IP Barriers 00:11:36 – Global Competition, Government Subsidies, and Medical Tourism 00:16:43 – Operational Cost Reduction: Vendor Lock-In, Expediting Fees, and Modular Systems 00:20:50 – Tech Transfer Realities: The Limits of Paper SOPs and Scaling Microliters to Liters 00:26:26 – Asset Acquisition vs. Building from Scratch 00:33:27 – Supply Chain Vulnerabilities, Reagent Shortages, and Modular Platforms
Designing for Resilience: Why CGT Supply Chain Begins Years Before Tech Transfer | Mehran Bhatti
2026/08/18
How do 1 in 16 cell and gene therapies fail, not because of the biology, but because of the supply chain? In this episode of Out of the Lab, host Nico sits down with Mehran, a seasoned Cell & Gene Therapy supply chain consultant, to dissect why operational resilience must be engineered into your product long before tech transfer ever takes place. From CDMO selection gaps to un-addressable spend and non-standard Bill of Materials (BOM) choices, Mehran exposes the hidden operational traps that trigger FDA Complete Response Letters (CRLs) and derail launches. In this episode, we cover: Who Owns Resilience? Why supply chain expertise must intersect with early CMC and process development. The CDMO Bottleneck: Unpacking why 40% of manufacturing-related FDA hurdles stem from partner selection and process optimization gaps. Addressable vs. Non-Addressable Spend: Why 42% of materials get locked in filings and how to optimize raw material selection up front. Real-World Harmonization: Lessons from J&J’s Carvykti pipeline on managing apheresis variability and standardizing network supply. The Future of Orchestration: How AI and predictive analytics are transforming patient slotting, scheduling, and apheresis quality. Timestamps & Chapters: 00:00 – Introduction: Supply chain resilience in Cell & Gene Therapy 02:03 – Who owns resilience? Bridging CMC, process development, and supply chain 04:57 – CDMO partner selection & commercial readiness 06:21 – The cost of failure: CRLs, manufacturing quality, and CDMO gaps 08:05 – Process ownership vs. CDMO lock-in: Lessons from J&J and apheresis 12:21 – Addressable vs. non-addressable spend in biomanufacturing 16:38 – The 50 mL Syringe Example: Why process engineers need supply chain optics 20:15 – Geopolitical risk, tariffs, and global facility harmonization 24:18 – Built-in network resilience: Lessons from radiopharmaceuticals 28:20 – Logistics, cold-chain, and patient orchestration in Europe vs. US 34:34 – The role of data, AI, and predictive analytics in apheresis quality
You Can’t Test Quality Into a Product: FDA Import Alerts & GXP with Wynngate Consulting
2026/08/11
What happens when a foreign manufacturer gets put on an FDA import alert? Or when a single undocumented ingredient turns a harmless dietary supplement into an unapproved drug? In this episode of Out of the Lab, host Nico sits down with Dan and Binh from Wynngate Consulting. Bringing decades of insider FDA experience from compliance enforcement to foreign facility inspections, they pull back the curtain on the operational realities of GXP manufacturing. We explore the massive regulatory shifts brought on by the Food Safety Modernization Act (FSMA) and why the FDA's Foreign Supplier Verification Program has changed the game for importers. In this episode, we cover: The Overlapping 50%: The surprising similarities and critical differences between dietary supplement GMPs (Part 111) and pharmaceutical GMPs (Part 211). The "Checking the Box" Trap: How an inadequate response to an FDA 483 observation can escalate into an Import Alert and a 10-year remediation nightmare. Intentional vs. Accidental Adulteration: From shared line cross-contamination to companies secretly lacing weight-loss supplements with active pharmaceuticals to dodge clinical trials. The Old FDA Adage: Why you can never test quality into a product once underlying GMP violations exist. Supply Chain Resilience: Why vetting your foreign CDMO's quality management system is the ultimate risk mitigation technique for drug sponsors. Dan and Binh consult on GxP compliance at Wynngate Consulting.Connect with them: Dan Simonsen, Vice President: https://www.linkedin.com/in/danjsimonsen/ Binh Nguyen, President: https://www.linkedin.com/in/binh-nguyen-a77046190/ Visit their website:https://www.wynngateconsulting.com/
Why Yield Isn't King: Analytics & Tech Transfer Lessons with Forge Biologics CTO David Dismuke
2026/07/28
What are the hidden operational mistakes early-stage drug developers make before ever selecting a CDMO? In this episode of Out of the Lab, host Nicholas Crudele sits down with David Dismuke, Chief Technology Officer at Forge Biologics. Drawing on over 20 years of experience across both academic CDMOs, corporate CDMOs, and therapeutic developers, David breaks down why yield should not be your only metric, how host cell DNA and empty/full ratios impact clinical timelines, and why a low-CV potency assay is your ultimate insurance policy during tech transfer. In this episode, we cover: The Yield Trap: Why focusing solely on viral titer masks critical quality attributes (CQAs) that can derail regulatory filings. Empty vs. Full Capsid Ratios: Managing host cell DNA trade-offs and understanding route of administration impacts. Potency Assays as Comparability Anchors: How high-throughput, sound analytical methods allow you to innovate safely in GMP environments. Two-Sided Tech Transfer: Why you should never "throw the process over the wall" and how to execute proper gap analyses with your CDMO. Single-Use Equipment: Navigating downstream chromatography hurdles and eliminating multi-product contact risks.
The Holy Grail of MES: Why Paperwork Isn't Process Control | Robert Perks
2026/07/28
Why do biomanufacturing execution systems fail despite multi-million dollar investments? In this episode of Out of the Lab, host Nicholas Crudele sits down with biopharma automation and manufacturing execution system (MES) consultant Robert Perks to unpack the realities of digitizing biomanufacturing workflows. From early R&D data integration to navigating the FDA’s shift toward Computer Software Assurance (CSA), Robert shares what it actually takes to achieve release by exception. Key Topics Covered: Cross-Functional Ownership: Why MES implementations fail when controlled by a single department. CSV to CSA Shift: Moving away from binders of paper to risk-based critical thinking. Designing for the Operator: Eliminating duplicated data entry and friction on the cleanroom floor. Bridging R&D and Manufacturing: Leveraging early KPI and CQA data to build standardized Master Batch Records (MBRs). Release by Exception: What infrastructure is required to make automated batch release a reality. Timestamps: 00:00:00 – Introduction & Operational Scope 00:01:14 – What is an MES & Who Needs a Seat at the Table? 00:03:12 – When Should Early Biotechs Engage with MES? 00:07:55 – Operator Optimization & Reducing Data Duplication 00:11:46 – The Regulatory Paradigm Shift: From CSV to CSA 00:18:48 – Integrating R&D Data into Scale-Up Master Batch Records 00:26:44 – The Holy Grail: Achieving Release by Exception

Podcast reviews

Read Method Made: The Tech Transfer Edge in Cell & Gene Therapy podcast reviews


0 out of 5
0 reviews

Podcast sponsorship advertising

Start advertising on Method Made: The Tech Transfer Edge in Cell & Gene Therapy relevant audience podcasts


What do you want to promote?